Breaking News Instant updates and real-time market news.

NBIX

Neurocrine

$42.30

0.03 (0.07%)

07:07
10/18/16
10/18
07:07
10/18/16
07:07

Neurocrine initiated with a Buy at Needham

Needham analyst Alan Carr initiated Neurocrine with a Buy and a $62 price target.

  • 20

    Oct

  • 21

    Oct

  • 06

    Nov

  • 29

    Nov

  • 14

    Dec

NBIX Neurocrine
$42.30

0.03 (0.07%)

10/04/16
LEER
10/04/16
INITIATION
Target $70
LEER
Outperform
Neurocrine reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of Neurocrine with an Outperform rating and $70 price target.
10/06/16
LEHM
10/06/16
DOWNGRADE
Target $50
LEHM
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.
10/12/16
LEER
10/12/16
NO CHANGE
Target $70
LEER
Outperform
Neurocrine recent selloff a buying opportunity, says Leerink
Leerink analyst Paul Matteis views the 18% pullback in shares of Neurocrine Biosciences (NBIX) over the past few weeks as a buying opportunity. The analyst finds the catalyst for the selloff "difficult to pinpoint," but notes he's been receiving questions from investors on the size of the market opportunity for vesicular monoamine transporters in Tardive Dyskinesia. A doctor survey suggests a target market of 300,000 TD patients for Neurocrine's and Teva's VMAT2 inhibitors, which is enough to offer a "significant revenue opportunity" for both drugs, Matteis tells investors in a research note. Further, the analyst believes the upcoming Phase II data in Tourette's Syndrome, which he sees as having a high probability of success, offers a "nice catalyst for investors" into Q1 of next year. Matteis reiterates an Outperform rating on Neurocrine with a $70 price target.
10/13/16
BMOC
10/13/16
NO CHANGE
BMOC
Neurocrine recent weakness unwarranted, says BMO Capital
BMO Capital analyst M. Ian Somaiya says that Neurocrine (NBIX) has been weak recently in the wake of Myovant's S-1 filing. According to the analyst, investors view Myovant's relugolix as a more convenient alternative to Neurocrine's elagolix. However, the analyst thinks that relugolix's longer half-life "could complicate add-back therapy," while the wording of the questionnaire for relugolix's Phase 3 trial increases endometriosis clinical development risk. Additionally, the analyst says that Neurocrine's elagolix has a two to three year lead time over relugolix, setting the stage for both drugs to do well. He keeps a $66 price target and Outperform rating on Neurocrine.

TODAY'S FREE FLY STORIES

INN

Summit Hotel Properties

$15.46

0.1 (0.65%)

05:20
09/26/17
09/26
05:20
09/26/17
05:20
Upgrade
Summit Hotel Properties rating change  »

Summit Hotel Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

DRE

Duke Realty

$29.28

0.17 (0.58%)

05:17
09/26/17
09/26
05:17
09/26/17
05:17
Downgrade
Duke Realty rating change  »

Duke Realty downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REXR

Rexford Industrial

$29.56

0.05 (0.17%)

05:15
09/26/17
09/26
05:15
09/26/17
05:15
Downgrade
Rexford Industrial rating change  »

Rexford Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCO

Taubman Centers

$50.00

0.86 (1.75%)

05:14
09/26/17
09/26
05:14
09/26/17
05:14
Downgrade
Taubman Centers rating change  »

Taubman Centers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

  • 11

    Oct

KIM

Kimco Realty

$19.58

0.4 (2.09%)

05:11
09/26/17
09/26
05:11
09/26/17
05:11
Upgrade
Kimco Realty rating change  »

Kimco Realty upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

GGP

GGP

$20.75

0.25 (1.22%)

05:11
09/26/17
09/26
05:11
09/26/17
05:11
Upgrade
GGP rating change  »

GGP upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAC

Macerich

$54.16

1.44 (2.73%)

05:10
09/26/17
09/26
05:10
09/26/17
05:10
Upgrade
Macerich rating change  »

Macerich upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DY

Dycom

$81.23

-1.46 (-1.77%)

05:06
09/26/17
09/26
05:06
09/26/17
05:06
Initiation
Dycom initiated  »

Dycom initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

PNC

PNC Financial

$133.52

0.09 (0.07%)

, GS

Goldman Sachs

$230.26

-0.77 (-0.33%)

05:04
09/26/17
09/26
05:04
09/26/17
05:04
Downgrade
PNC Financial, Goldman Sachs, Wells Fargo, Morgan Stanley, JPMorgan rating change  »

PNC Financial downgraded…

PNC

PNC Financial

$133.52

0.09 (0.07%)

GS

Goldman Sachs

$230.26

-0.77 (-0.33%)

WFC

Wells Fargo

$54.03

-0.22 (-0.41%)

MS

Morgan Stanley

$47.74

-0.48 (-1.00%)

JPM

JPMorgan

$94.12

-0.71 (-0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 03

    Oct

  • 12

    Oct

  • 13

    Oct

  • 13

    Oct

  • 17

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

JPM

JPMorgan

$94.12

-0.71 (-0.75%)

05:01
09/26/17
09/26
05:01
09/26/17
05:01
Downgrade
JPMorgan rating change  »

JPMorgan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 12

    Oct

  • 22

    Oct

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

JWN

Nordstrom

$47.32

0.44 (0.94%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Nordstrom management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BMY

Bristol-Myers

$63.19

-0.17 (-0.27%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Bristol-Myers management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

MCO

Moody's

$138.78

0.75 (0.54%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Moody's management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

ALB

Albemarle

$128.89

-5.4 (-4.02%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Albemarle management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

AFSI

AmTrust

$12.98

-0.3 (-2.26%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
AmTrust management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

NEE

NextEra Energy

$146.82

0.46 (0.31%)

, AES

AES Corp.

$11.21

0.1 (0.90%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Wolfe Research to hold a conference »

Utilities & Power…

NEE

NextEra Energy

$146.82

0.46 (0.31%)

AES

AES Corp.

$11.21

0.1 (0.90%)

PEGI

Pattern Energy

$25.53

-0.37 (-1.43%)

LNT

Alliant Energy

$42.25

0.52 (1.25%)

AGR

Avangrid

$47.10

0.6 (1.29%)

PNW

Pinnacle West

$86.85

0.7 (0.81%)

ETR

Entergy

$77.76

1.01 (1.32%)

PEG

PSEG

$46.50

0.31 (0.67%)

AWK

American Water

$82.48

0.45 (0.55%)

CMS

CMS Energy

$47.10

0.63 (1.36%)

AEP

American Electric

$71.04

0.47 (0.67%)

D

Dominion

$78.02

0.98 (1.27%)

ED

Consolidated Edison

$82.24

0.65 (0.80%)

ES

Eversource

$61.47

0.76 (1.25%)

EIX

Edison International

$79.27

0.99 (1.26%)

DUK

Duke Energy

$85.14

0.89 (1.06%)

DTE

DTE Energy

$109.74

1.36 (1.25%)

FE

FirstEnergy

$31.11

0.22 (0.71%)

WEC

WEC Energy

$64.24

0.63 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 02

    Oct

  • 02

    Oct

  • 05

    Nov

  • 29

    Nov

DNOW

NOW Inc.

$13.26

0.27 (2.08%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
NOW Inc. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 01

    Nov

ALGT

Allegiant Travel

$133.95

3.85 (2.96%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Allegiant Travel management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

XPER

Xperi

$24.70

-0.35 (-1.40%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Xperi management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

OZRK

Bank of the Ozarks

$45.90

0.34 (0.75%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Bank of the Ozarks management to meet with Piper Jaffray »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

  • 29

    Sep

04:55
09/26/17
09/26
04:55
09/26/17
04:55
General news
Consumer Confidence to be reported at 10:00 »

September Consumer…

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Citigroup to hold a forum »

Pan Asia Corporate Forum…

BGG

Briggs & Stratton

$22.93

0.24 (1.06%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
Briggs & Stratton management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

PLUS

ePlus

$87.95

-0.65 (-0.73%)

04:55
09/26/17
09/26
04:55
09/26/17
04:55
Conference/Events
ePlus management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

04:55
09/26/17
09/26
04:55
09/26/17
04:55
General news
Breaking General news story  »

Federal Reserve Chair…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.